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Introduction
Cell surface proteoglycans are key players in epithelial morpho-
genesis. They form gradients that immobilize mitogens in prox-
imity to signaling receptors (Wang and Laurie, 2004; Häcker 
et al., 2005; Radtke and Clevers, 2005), contribute to cellular 
adhesion by ligating the ECM, and at least in one case partici-
pate in integrin coupling (Beauvais et al., 2004; McQuade et al., 
2006). Cell surface proteoglycans consist of a core protein and 
associated glycosaminoglycan chains, mainly heparan sulfate (HS). 
Current dogma states that mitogen, cytokine, and ECM binding 
is largely the domain of the anionic HS chains (Couchman 2003; 
Häcker et al., 2005). HS chains are generated by a complement 
of Golgi polymerases, epimerase, and sulphotransferases during 
posttranslational modifi  cation. Each is thought to vary in relative 
activity by cell or tissue type (Perrimon and Bernfi  eld, 2000). 
Thus, within a given epithelium or endothelium, a structurally 
similar HS chain can be attached to genetically   distinct core 
protein (Zako et al., 2003).
New work has shed light on how HS proteoglycan speci-
fi  city is generated in development and disease. Most involve ex-
tracellular enzymes that affect cell surface HS proteoglycans in 
unexpected ways. Removal of certain HS 6-O-sulfates by endo-
6-O-sulfatases Sulf1 and -2 disrupts the binding of the bone 
morphogenetic protein inhibitor Noggin, leading to its dispersal 
and establishment of bone morphogenetic protein signaling 
  (Viviano et al., 2004). In contrast, this same HS modifi  cation 
  diminishes FGF binding and assembly with its signaling receptor 
(Dai et al., 2005). In another extracellular modifi  cation mecha-
nism, HS cleavage by heparanase generates soluble fragments of 
HS that form complexes of FGF–HS and trigger cellular prolifer-
ation, migration, and angiogenesis (Kato et al., 1998). In another 
mechanism, matrix metalloproteinase-7–dependent shedding 
of the entire syndecan ectodomain promotes cancer-associated 
up-regulation of glypican-1 and tumor growth (Ding et al., 2005).
In addition to its HS-dependent signaling mechanisms, re-
cent work has shown that the syndecan core proteins themselves 
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  C
ell surface heparan sulfate (HS) proteoglycans are 
carbohydrate-rich regulators of cell migratory, mi-
togenic, secretory, and inﬂ  ammatory activity that 
bind and present soluble heparin-binding growth factors 
(e.g., ﬁ  broblast growth factor, Wnt, Hh, transforming growth 
factor β, amphiregulin, and hepatocyte growth factor) to 
their respective signaling receptors. We demonstrate that 
the deglycanated core protein of syndecan-1 (SDC1) and 
not HS chains nor SDC2 or -4, appears to target the epi-
thelial selective prosecretory mitogen lacritin. An important 
and novel step in this mechanism is that binding necessi-
tates prior partial or complete removal of HS chains by en-
dogenous heparanase. This limits lacritin activity to sites 
where heparanase appears to predominate, such as sites 
of exocrine cell migration, secretion, renewal, and inﬂ  am-
mation. Binding is mutually speciﬁ  ed by lacritin’s C-terminal 
mitogenic domain and SDC1’s N terminus. Heparanase 
modiﬁ  cation of the latter transforms a widely expressed 
HS proteoglycan into a highly selective surface-binding 
protein. This novel example of cell speciﬁ  cation through 
extracellular modiﬁ  cation of an HS proteoglycan has broad 
implications in development, homeostasis, and disease.
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participate as cell surface receptors. Their extracellular protein do-
mains regulate the activation of integrins (Beauvais and  Rapraeger, 
2003; Beauvais et al., 2004; McQuade et al. 2006); bind growth 
factors, including Wnt, midkine, and pleitrophin (Deepa et al. 
2004; Capurro et al., 2005); and disrupt carcinoma activity when 
added as recombinant competitors, presumably by disrupting their 
assembly with other signaling receptors at the cell surface.
Here, we report on a novel mechanism of syndecan-1 
(SDC1) signaling that relies on a direct binding interaction of 
the extracellular core protein domain of the syndecan and modi-
fi   cation of the proteoglycan by HS-modifying enzyme. The 
mechanism involves the partially characterized prosecretory 
  mitogen lacritin, discovered as a consequence of a search for 
  epithelial differentiation factors (Sanghi et al., 2001). Lacritin is a 
small (12.3 kD) epithelial-selective human glycoprotein.  Lacritin 
signals to stromal interaction molecule 1, mammalian   target of 
rapamycin, and nuclear factor of activated T cells 1 (NFATC1) 
via rapid PKCα dephosphorylation and phospholipase D activa-
tion (Wang et al., 2006) to potentially regulate differentiation, 
renewal, and secretion by the nongermative exocrine epithelia 
that it preferentially targets. With the exception of pancreatic 
β-cells (Dor et al., 2004), mechanisms of nongermative epithe-
lial differentiation and renewal are poorly understood. Lacritin-
deletion analysis identifi  ed a C-terminal mitogenic domain with 
amphipathic α-helical structure (Wang et al., 2006) common to 
many ligand–receptor or ligand–ligand binding sites (Barden 
et al., 1997; Siemeister et al., 1998). We report here that lacritin’s 
C terminus targets the SDC1 core protein as a prerequisite for 
mitogenesis. A second and novel prerequisite is prior modifi  ca-
tion or removal of HS from the syndecan by heparanase-1. 
We postulate that the localized action of heparanase converts 
a widely expressed cell surface proteoglycan into a localized 
  lacritin-binding protein that is   required for mitogenic signaling.
Results
Lacritin targets cell surface SDC1
Lacritin promotes epithelial proliferation at low nanomolar 
  levels, suggesting a cell surface–binding Kd in the nanomolar 
range suffi  cient for affi  nity purifi  cation of its receptor. An 
  apparent 190-kD cell surface protein eluted from lacritin but not 
control columns after incubation with detergent lysates of sur-
face biotinylated human salivary gland ductal (HSG) cells 
in buffer containing physiological levels of NaCl (Fig. 1). 
 Sequencing  identifi  ed the 190-kD protein as a multimer of hu-
man SDC1, a transmembrane proteoglycan that acts as a core-
ceptor for mitogenic signaling by binding heparin binding 
growth factors such as FGFs, Wnts, Hhs, and hepatocyte growth 
factors via its HS glycosaminoglycan chains (Alexander et al., 
2000; Esko and Selleck, 2002).
To assess this interaction by affi  nity precipitation, we cre-
ated a 293T cell line stably expressing human SDC1 and treated 
lacritin or positive control FGF2 precipitates with bacterial hep-
aritinase and chondroitinase to remove the large and heteroge-
nous glycosaminoglycan chains. The supernatant and pellet of 
the digest were then separately blotted for SDC1 using mAb 
B-B4 directed against the core protein. This revealed 190- and 
80-kD bands, confi  rming the multimeric nature of the 190-kD 
Figure 1.  Lacritin afﬁ  nity  puriﬁ   cation of cell surface SDC1. Detergent 
  lysates of surface biotinylated HSG cells were incubated overnight in deter-
gent and physiological NaCl with intein-chitin columns either lacking (A) or 
containing (B) lacritin. After extensive washing in the same buffer, the 
  columns were eluted with 1 M NaCl, and eluted proteins were identiﬁ  ed 
by blotting with streptavidin-peroxidase. A predominant 190-kD biotinyl-
ated protein eluting from the lacritin column was identiﬁ  ed by mass spec-
trometry as human SDC1.
Figure 2.  Lacritin binding to SDC1 is independent of complete HS/CS 
  glycosaminoglycans.  (A) Lacritin afﬁ   nity precipitation of human SDC1 
  multimers stably expressed by HEK293T cells. Lacritin-intein beads were 
incubated with cell lysates, washed extensively, and treated with heparitin-
ase I/chondroitinase ABC. Pellet (P) and supernatant (S) from the centri-
fuged digest were then blotted with mAb B-B4 for SDC1 core protein. 
(B) Lacritin-intein, lacritin-GST, FGF2-GST, intein, and GST beads were in-
cubated with lysates from the same HEK293T cells stably expressing 
  human SDC1. Precipitates were washed, treated, centrifuged, and blotted 
as in A. (C) Lacritin-intein and FGF2-GST beads were incubated with lysate 
of HEK293T cells stably expressing human SDC2 or lysate of another 
HEK293T cell line stably expressing human SDC4. Beads were washed, 
treated, and centrifuged as in A. Blots were detected with anti-SDC2 mAb 
L-18 or anti-SDC4 mAb N-19, respectively. A shows both 190- and 80-kD 
bands. B and C and all subsequent ﬁ  gures show the 80-kD band, which is 
more predominant in HEK293T transfectants.SYNDECAN-1 BINDS THE PROSECRETORY MITOGEN LACRITIN • MA ET AL.    1099
SDC1 band (Fig. 2 A). Lacritin-bound SDC1 was consistently 
detected in the pellet, implying that the ligation was not solubi-
lized by heparitinase/chondroitinase digestion and therefore 
may involve the core protein. In keeping with this possibility, 
lacritin did not target SDC2 or -4 (Fig. 2 C) that share HS chains 
but only 27–28% ectodomain identity with SDC1. FGF2, as ex-
pected, bound all three syndecans via heparitinase-cleavable 
HS (Fig. 2, B and C).
SDC1 binding via a lacritin 
C-terminal domain
Lacritin truncation analysis recently identifi  ed a C-terminal 
  mitogenic domain capable of forming an amphipathic α helix as 
per the receptor-binding domain of parathyroid hormone-like 
protein (Wang et al., 2006). Could SDC1 binding and mitogenic 
sites be shared? SDC1 binding was unaffected by deletion (Fig. 
3 A) of 5 and 10 amino acids from the C terminus (Fig. 3 B) or 15 
and 24 amino acids from the N terminus (Fig. 3 C) of lacritin. 
However, affi  nity was substantially diminished after fi  ve more 
C-terminal amino acids were deleted (C-15) and completely 
abolished from C-25 and C-49 lacritin (Fig. 3 B). These data 
point to a binding site between amino acids 100 and 109 of ma-
ture lacritin that mirrors the mitogenic domain. To validate and 
further probe this observation, lacritin-SDC1 affi  nity precipita-
tions were competitively challenged with the truncated lacritin 
mutants (Fig. 4). Soluble lacritin and N-24, but not C-25 and 
C-59, inhibited binding. Also inhibitory was recombinant 
  human SDC1 core protein (hS1ED) expressed in Escherichia coli, 
but not HS, CS, or human SDC2 or -4. Collectively, these data 
suggest that ligation of SDC1 is specifi  ed by a region within 
lacritin’s C terminus that appears to show affi  nity for SDC1’s 
core protein but not HS or CS.
SDC1 is required for lacritin mitogenesis
Because mitogenic (Wang et al., 2006) and SDC1-binding 
  domains map to the same 10-amino-acid region, we questioned 
whether competition with recombinant hS1ED would disrupt 
lacritin-dependent mitogenesis. Soluble hS1ED inhibited pro-
liferation of lacritin-stimulated HSG cells in a dose-dependent 
manner. The same inhibitory doses had no effect on C-25–
treated cells or on FBS-stimulated proliferation (Fig. 5 A). To 
approach this question differently, HSG cells were depleted of 
SDC1 by siRNA (Fig. 5 C). Dose-dependent depletion of SDC1, 
but not depletion of SDC2 (Fig. 5 C), completely abrogated 
  lacritin mitogenic responsiveness (Fig. 5 B). Lacritin signals 
through Gαi or Gαo/PKCα-PLC/Ca
2+/calineurin/NFATC1/ 
cyclooxygenase (COX) 2 toward mitogenesis (Wang et al., 
2006). We therefore examined COX2 expression in SDC1- and 
SDC2-depleted cells. In SDC1 but not SDC2 knockdown cells, 
lacritin-dependent COX2 expression was absent (Fig. 5 D). 
Figure 3.  Lacritin’s C terminus binds SDC1. (A) Schematic diagram of lac-
ritin with dotted lines indicating N- and C-terminal truncations. All lacritin 
truncations were expressed as intein fusion proteins for afﬁ  nity precipita-
tion. The asterisk indicates mitogenic domain (Wang et al., 2006), and 
boxes represent PSIPRED-predicted α helices. (B) Lacritin-, C-5–, C-10–, 
C-15–, C-25–, and C-59–intein beads were incubated with lysates from 
HEK293T cells stably expressing human SDC1. Beads were washed and 
treated with heparitinase I/chondroitinase ABC. The digests were centri-
fuged, and pellets (P) and supernatants (S) blotted with mAb B-B4 for SDC1 
core protein, all as in Fig. 2. (C) Incubation of lacritin-, N-15– and 
N-24–intein beads with the same human SDC1 lysates was followed with 
identical washing, heparitinase I/chondroitinase ABC digestion, centrifu-
gation, and B-B4 mAb blotting. Lys, lysate.
Figure 4.  Lacritin-SDC1 binding is inhibited by soluble hS1ED, lacritin, 
and N-24, but not by C-25, C-59, HS, CS, SDC2, or SDC4. (A, top) Lacritin-
intein beads were incubated with human SDC1 lysates from stably express-
ing HEK293T cells in the presence of increasing amounts of soluble HS 
(70–700 μg), HS (700 μg) plus CS (700 μg), or lacritin (14–700 μg) or 
no inhibitor (−). The quantity of soluble inhibitor was calibrated relative to 
the  7–8 μg of human SDC1 elutable from lacritin-intein beads with 1 M 
NaCl. After incubation, beads were washed extensively and treated with 
heparitinase I/chondroitinase ABC. The digests were centrifuged, and 
  pellets were blotted with mAb B-B4 for SDC1 core protein, as in Fig. 2. 
  (bottom) Lacritin-intein beads were incubated with human SDC1 lysates in 
the presence of soluble N-24, C-25, C-59 (14 μg of each), increasing 
amounts of bacterially expressed human SDC1 ectodomain (hS1ED; 
35–700 μg), or with HEK293T cell–expressed native SDC2 or -4 (70 μg 
of each). Beads were washed and treated as above. (B) Quantiﬁ  cation of 
inhibition binding. Error bars indicate SEM.JCB • VOLUME 174 • NUMBER 7 • 2006  1100
  Ligation of SDC1 thus appears to be a required upstream step in 
lacritin mitogenic signaling.
Lacritin and FGF2 target different 
forms of SDC1
We noted how biotinylated SDC1 from surface-labeled HSG 
cells was selectively purifi  ed on lacritin affi  nity columns and 
that it migrated as a relatively distinct band (Fig. 1) without 
prior heparitinase/chondroitinase to excise the heterogenous HS 
and CS chains. In contrast, native SDC1 without digestion pres-
ents as a broad smear (Fig. S1, available at http://www.jcb.org/
cgi/content/full/jcb.200511134/DC1). Also, lacritin affi  nity pre-
cipitated SDC1 was retained in the pellet after heparitinase/
chondroitinase digestion. Could the sharply defi  ned 190- and 
80-kD bands represent a minor deglycanated or hypoglycosyl-
ated form preferentially enriched because of lacritin’s apparent 
core protein–related affi  nity? To explore this possibility, we 
  sequentially depleted either FGF2- or lacritin-bindable SDC1 
from lysates and then challenged the depleted lysates with lac-
ritin or FGF2 affi  nity precipitation, respectively (Fig. 6).  Affi  nity 
precipitates were treated with heparitinase/chondroitinase be-
fore SDS-PAGE to simplify mAb B-B4 detection of the core 
protein in the digest supernatant (FGF2) or pellet (lacritin). 
Successive pull-down with FGF2-GST depleted all FGF2-
  bindable SDC1 (Fig. 6 A, lanes 1–3). Interestingly, the amount 
of SDC1 available to interact with lacritin-intein was unaffected 
(Fig. 6 A, lane 4 vs. lanes 1 and 9). Similarly, depletion of SDC1 
with lacritin-intein slightly but not substantially diminished SDC1 
binding to FGF2-GST (Fig. 6 A, lanes 5–7 vs. lanes 8 and 10). 
This implies that two pools of SDC1 may be available. One 
is apparently native SDC1, to which lacritin appears to lack 
 affi  nity. The other may be an HS-free or partially deglycanated 
form of SDC1. Could the latter be an immature intracellular 
form? This appears not to be the case. When cells were gently 
trypsinized before lysis, no lacritin-bindable SDC1 was de-
tected (Fig. 6 B) in keeping with the original purifi  cation of 
  labeled SDC1 from surface biotinylated cells (Fig. 1). Also 
ruled out was bacterial heparitinase contamination of recombi-
nant lacritin. We took advantage of 3G10 mAb directed against 
a desaturated uronate epitope generated by heparitinase diges-
tion (David et al., 1992) and could detect lacritin-bound SDC1 
only after treatment with exogenous heparitinase (Fig. 6 C). 
That heparitinase can create the 3G10 epitope is revealing, for 
it points to the presence of HS or HS stubs on the core protein 
that is recognized by lacritin. HS stubs could be generated by 
  heparanase, a eukaryotic endo-β-d-glucuronidase that cleaves 
the entire HS chains between GlcUA and GlcNAc linkages. 
Collectively, these data suggest that lacritin and FGF2 target 
different forms of cell surface SDC1. SDC1 bound by lacritin is 
less   heterogenous, suggesting that although it is decorated with 
 suffi  cient HS to be recognized by heparitinase, much of its HS 
has been removed.
Heparanase-dependent lacritin mitogenesis
One hypothesis to explain these data is that heparanase- sensitive 
HS sterically blocks lacritin binding to a latent core protein site 
in native SDC1. If this is true, heparitinase digestion of native 
SDC1 should promote lacritin binding (Fig. 7 A). To study this 
possibility, SDC1 from cell lysates was purifi  ed on FGF2-GST, 
washed, salt eluted, heparitinase digested, and incubated with 
lacritin-intein (Fig. 7 A, lane 1 [0.5 M NaCl eluate] and lane 2 
[1.0 M NaCl eluate]). As controls, SDC2 and -4 from cell 
 lysates  were  individually purifi  ed on FGF2-GST, washed, salt 
eluted, heparitinase digested, and incubated with lacritin-intein 
Figure 5.  SDC1 is required for lacritin-dependent mitogenesis and COX2 
expression. (A) Proliferation assay in which HSG cells were grown for 
24 h in serum-free media containing 10 nM lacritin, 10 nM C-25 lacritin, 
or FBS in the absence or presence of increasing amounts of soluble hS1ED. 
(B) Identically performed proliferation assay in which HSG cells were 
treated with 10 nM lacritin or FBS 48 h after being mock transfected or 
transfected with 10 nM of Ambion’s negative control siRNA #1 (neg), 
1–100 nM SDC1 siRNA, or 10 nM SDC2 siRNA. Error bars indicate SEM. 
(C, top) RT-PCR and Western blotting of mock versus 10 nM SDC1 siRNA–
treated cells. RT-PCR is for SDC1 and -2 mRNAs. Blotting is with mAb B-B4 
for SDC1 core protein or with anti-GAPDH. (bottom) RT-PCR for SDC2 
mRNA in mock-transfected cells or cells transfected with 10 nM SCD2 
siRNA. (D) RT-PCR of COX2 expression by HSG cells without (−) or with 
(+) 10 nM lacritin stimulation. 48 h earlier, the cells were mock transfected 
or transfected with 10 nM SDC1, 10 nM SDC2, or 1 nM heparanase-1 
(HPSE-1) siRNAs. At bottom is GAPDH expression.SYNDECAN-1 BINDS THE PROSECRETORY MITOGEN LACRITIN • MA ET AL.    1101
(Fig. 7 A, SDC2 [lane 3, 0.5 M NaCl eluate; lane 4, 1.0 M NaCl 
eluate] and SDC4 [lane 5, 0.5 M NaCl eluate; lane 6, 1.0 M NaCl 
eluate]). Affi  nity precipitates were heparitinase/chondroitinase 
(+) treated before SDS-PAGE and blotting for SDC1, -2, or -4. 
We observe that FGF2-purifi  ed SDC1, but not FGF2-purifi  ed 
SDC2 or -4, can indeed bind lacritin after heparitinase treat-
ment (Fig. 7 A,  lanes 1 and 2), presumably by exposing a hid-
den site. Where does lacritin bind? Steric hindrance by the 
N-terminal HS chains suggests that lacritin may bind SDC1’s N 
terminus. However, binding might occur elsewhere when con-
sideration is given to HS chain length and core protein folding. 
To examine these possibilities, we generated cell lines stably or 
transiently expressing human SDC1 lacking 51 N-terminal 
amino acids (del 1–51), lacking amino acids 51–252 of the 
  ecto  domain (del 51–252), or retaining only the N-terminal 
Figure 7.  Bacterial heparitinase digestion exposes FGF2-bindable SDC1 
to lacritin binding via a domain in SDC1’s N-terminal 50 amino acids. 
(A) Human SDC1 (lanes 1 and 2), SDC2 (lanes 3 and 4), and SDC4 (lanes 
5 and 6) from stably expressing HEK293T cells were individually puriﬁ  ed 
on FGF2-GST, eluted (0.5 and 1 M NaCl), treated with heparitinase 
I/chondroitinase ABC for 2 h, and incubated with lacritin-intein beads. 
  Blotting is with mAb B-B4 for SDC1, polyclonal antibody L-18 for SDC2, or 
polyclonal N-19 for SDC4—all core protein speciﬁ  c. (B) Schematic dia-
gram of human SDC1. The dotted line indicates truncation sites in the ect-
odomain forming the deletion constructs del 1–51, 51–252, and 51–310. 
Boxes represent PSIPRED-predicted α helices. Wavy lines represent HS 
and CS. TM, transmembrane domain. (C) Comparative incubation of 
FGF2-GST and lacritin-intein beads with human SDC1 or human SDC1 del 
1–51 lysates from stably expressing HEK293T cells. After incubation, 
beads were washed extensively and either treated with heparitinase 
I/chondroitinase ABC (+) or left untreated (−). Beads were centrifuged, 
and pellets (P) and supernatants (S) were blotted with mAb B-B4 for SDC1 
core protein. Lysate from HEK293T cells stably expressing SDC1 del 1–51 
is blotted in lanes 6 and 7. (D) Comparative incubation of lacritin-intein 
beads with human SDC1 del 51–252, 1–51, or 51–310 lysates from sta-
bly or transiently expressing HEK293T cells. pcDNA is lysate from cells 
transfected with vector only. After incubation, beads were washed exten-
sively and treated with heparitinase I/chondroitinase ABC. Beads were 
centrifuged, and pellets were blotted with mAb 3G10 for desaturated 
  uronates in SDC1.
Figure 6.  Lacritin and FGF2 bind different forms of cell surface SDC1. 
(A) Sequential afﬁ  nity precipitation assays. Lanes 1–3 show lysate from 
human SDC1 stably expressing HEK293T cells sequentially incubated with 
three rounds of fresh FGF2-GST beads. Half of the ﬁ  nal depleted lysate was 
then incubated with lacritin-intein beads (lane 4), and the other half was 
methanol precipitated (lane 9). Similarly, in lanes 5–7, a different aliquot 
of lysate from the same cells was sequentially incubated with three rounds 
of fresh lacritin-intein beads. Half of the ﬁ  nal depleted lysate was then incu-
bated with FGF2-GST beads (lane 8), and the other half was methanol pre-
cipitated (lane 10). Beads were washed and treated with heparitinase 
I/chondroitinase ABC. The digests were centrifuged, and pellets (P) and su-
pernatants (S) were blotted with mAb B-B4 for SDC1 core protein. Shown 
are digest supernatants (lanes 1–3 and 8) and pellets (lanes 4–7) as per 
heparitinase release of FGF2-bound or resistance of lacritin-bound SDC1, 
respectively. (B) HEK293T cells stably expressing human SDC1 were either 
lysed as usual or ﬁ  rst brieﬂ  y trypsinized (<5 min; 0.05%) and then treated 
with serum to inactivate trypsin, washed, and lysed. Both lysates were 
incubated with lacritin-intein beads. Beads were washed and treated with 
heparitinase I/chondroitinase ABC. The digests were centrifuged, and pel-
lets (P) and supernatants (S) were blotted with mAb B-B4 for SDC1 core 
protein. (C) Lysates from HEK293T cells stably expressing human SDC1 
were incubated with lacritin-intein beads. Beads were washed and either 
left untreated (lane 1) or treated with heparitinase I/chondroitinase ABC 
(lanes 2 and 3). The treated sample was centrifuged. Pellet (lane 2), super-
natant (lane 3), untreated precipitate (lane 1), starting lysate (lane 4), and 
lacritin-intein solubilized from fresh lacritin-intein beads were blotted with 
mAb 3G10 for desaturated uronates in SDC1.JCB • VOLUME 174 • NUMBER 7 • 2006  1102
50 amino acids as a secreted form (del 51–310; Fig. 7 B). Del 
51–252 and 51–310 both bound lacritin, but not del 1–51 (Fig. 7, 
C and D), suggesting that SDC1’s N terminus is recognized 
by lacritin.
Although most heparanase is associated with endocytic 
compartments, the argument for an active cell surface role is 
compelling. Evidence includes heparanase secretion by acti-
vated endothelial (Chen et al., 2004) and T cells during infl  am-
mation (Fridman et al., 1987), antisense-inhibited cancer 
dissemination (Uno et al., 2001), and overexpression-associated 
migration of hair stem cell progeny (Zcharia et al., 2005). Is 
heparanase required for lacritin mitogenic binding of SDC1? 
Blotting for heparanase-1 detected the active 50-kD form that 
was enrichable on a HiTrap heparin column from both HSG and 
HEK293/SDC1 lysates (Fig. 8 A), in keeping with the known 
affi  nity of heparanase for heparin. The presence of heparanase 
in these fractions was confi  rmed in preliminary activity assays 
showing digestion of 
35SO4-labeled matrix (unpublished data). 
To assess whether heparanase-1 or -2 is required for lacritin-
  dependent proliferation, we treated HSG cells with siRNAs for 
each (Fig. 8, B and C). Heparanase-1 is abundantly expressed 
and, when knocked down, reduced lacritin-dependent prolifera-
tion to background in a dose-dependent manner. Importantly, 
the lowest effective doses did not affect EGF-dependent mito-
genesis, and depleted cells were rescued by addition of exoge-
nous heparanase or heparitinase (Fig. 8 C). In depleted cells 
without lacritin, neither had any effect (Fig. S2, available at 
http://www.jcb.org/cgi/content/full/jcb.200511134/DC1), thus 
eliminating the possibility that rescue was instead from hepa-
ranase signaling (Gingis-Velitski et al., 2004). Heparanase-2 
siRNA also had no effect (Fig. 8 C), but standard RT-PCR failed 
to detect heparanase-2 expression in untreated cells (not de-
picted), in keeping with real-time PCR detection of <15 mRNA 
copies/ng cDNA in human salivary gland (McKenzie et al., 
2000). We noted that lacritin mitogenic signaling promotes 
COX2 expression downstream of NFATC1 (Wang et al., 2006) 
and that siRNA depletion of SDC1, but not SDC2, abrogates 
lacritin-dependent COX2 expression (Fig. 5 D). If heparanase-1 
is functionally linked with SDC1 in lacritin mitogenic signaling, 
then depletion of heparanase-1 should have a similar effect. 
We observe in Fig. 5 D that this is indeed the case. Lacritin has 
no effect on COX2 expression in cells lacking heparanase-1.
Thus, it is apparent that two pools of SDC1 are available 
and that the lacritin-bindable pool is likely generated by hepa-
ranase. If this is true, the distribution of HS chain sizes in the 
FGF2-bindable versus lacritin-bindable pools should differ. 
To explore this possibility, each pool was isolated by affi  nity 
precipitation from 
35SO4-labeled cell lysates. After chondroi-
tinase digestion and elution with NaCl, HS was cleaved from 
the core protein with NaBH4 and analyzed by CL-6B gel fi  ltra-
tion chromatography (Fig. 8 D). In contrast to unimodal HS 
from the FGF2 pool (Kav = 0.3 – 0.33;  40 kD), HS from the 
lacritin pool was bimodal, with most 
35SO4 eluting with a Kav 
of 0.75–0.8. This corresponds to  4–5 kD. Both estimates 
are based on Waterson’s standard curve (Wasteson, 1971). 
  Interestingly, lower molecular mass HS was eliminated by 
  heparanase-1   depletion (Fig. 8 D). Collectively, these data suggest 
Figure 8.  Heparanase is expressed by HEK293T and HSG cells and is 
  required for lacritin-dependent mitogenesis. (A) Lysates of HSG cells 
(lane 1) and HEK293T cells stably expressing human SDC1 (lanes 2) 
  versus 2 M NaCl eluant of each after incubation with HiTrap heparin af-
ﬁ  nity columns (lanes 3 and 4, respectively). Blotting is with polyclonal 
anti–human heparanase-1 (HPSE1) antibody. (B) Lysates from HSG cells 
that had been mock transfected or transfected with 1 nM heparanase-1 
siRNA. Blotting is with polyclonal anti–human HPSE1 or anti-tubulin anti-
bodies. (C) Proliferation assay in which HSG cells were treated with 
10 nM lacritin or 1 nM EGF 48 h after being mock transfected 
or   transfected with 10 nM of Ambion’s negative control siRNA #1 (neg), 
1–100 nM HPSE1 siRNA, or 1 nM HPSE2 siRNA. Some HPSE1 siRNA 
cells were lacritin treated for 24 h in the presence of 1 μg of heparanase-
enriched eluant (A) from HEK293T cells stably expressing SDC1 (1 nM + 
HPSE) or 0.0001 U of bacterial heparitinase. Error bars indicate SEM. 
(D) Sepharose CL-6B gel ﬁ  ltration chromatography of HS from lacritin and 
FGF2 afﬁ   nity enriched SDC1 isolated from normal or HPSE1-depleted 
HSG cells. Lysates from cells labeled with 50 μCi/ml Na2
35SO4 in DME 
for 48 h were afﬁ  nity precipitated with FGF2-GST or lacritin-intein. Equal 
microgram amounts of SDC1 bound to beads were digested with chon-
droitin ABC lyase to remove CS, eluted with 2 M NaCl, and subjected to 
NaBH4 eliminative cleavage. Released HS was neutralized by drop-wise 
addition of 1 M HCl and subjected to Sepharose CL-6B gel ﬁ  ltration chro-
matography to compare the relative size of HS chains. V0, void volume 
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a mechanism whereby SDC1’s HS-rich N terminus is partially 
deglycanated by heparanase-1 to facilitate lacritin binding 
(Fig. 9) and signaling to mitogenic COX2.
Discussion
How cell surface proteoglycans specify regions of epithelial 
morphogenesis, homeostasis, or secretion is a central question 
in developmental biology. We report a new mechanism in which 
the N-terminal deglycanated core protein of SDC1, and not 
complete HS/CS chains nor SDC2 or -4, appears to target the 
epithelial selective prosecretory mitogen lacritin. An important 
and novel step in this approach is that binding necessitates prior 
complete or partial removal of HS chains by endogenous hepa-
ranase (Fig. 9). Limiting lacritin activity to specifi  c sites of 
  secreted heparanase thus transforms widely expressed SDC1 
into a regulated surface-binding protein.
Recent studies emphasize a growing appreciation for an 
interaction role of syndecan core proteins beyond the binding 
accomplished by their HS chains. Sdc1 regulates the activation 
of the αvβ3 and αvβ5 integrins in several cell types, an interac-
tion that depends on functional coupling between an extracel-
lular active site in the syndecan core protein and the integrins 
(Beauvais and Rapraeger, 2003; Beauvais et al., 2004;   McQuade 
et al., 2006). HS plus a short extracellular hydrophobic re-
gion near the transmembrane domain of mouse Sdc1 inhibits 
ARH-77 human B lymphoid cell invasion into collagen I 
(Langford et al., 2005). Recombinant human SDC2 core pro-
tein from E. coli mediates adhesion and proliferation of colon 
carcinoma cells (Park et al., 2002), and mouse Sdc4 contains a 
high-affi  nity cell-binding domain proximal to HS attachment 
sites (McFall and Rapraeger, 1997, 1998). Thus, the ectodo-
mains of syndecan core proteins mediate several morphoge-
netic and homeostatic events.
Lacritin’s preference for heparanase-deglycanated SDC1 
core protein is an interesting cell-targeting strategy that suc-
cessfully appropriates a ubiquitous proteoglycan for a role as a 
restrictive cell surface–binding protein. That this is feasible is a 
refl  ection of the rarity of SDC1 as a part-time or hypoglycosyl-
ated proteoglycan and the lack of general ectodomain sequence 
conservation among syndecans. Focal heparanase release may 
regulate lacritin’s mitogenic and prosecretory activity with un-
usual accuracy. Focal heparanase degradation of cell surface 
and ECM HS is implicated in glandular morphogenesis (Zcharia 
et al., 2004), stem cell migration (Zcharia et al., 2005), and cell 
survival (Cohen et al., 2006). It also plays a central role in in-
fl  ammation and cancer (Reiland et al., 2004). Activated endo-
thelial (Chen et al., 2004) and T cells secrete heparanase during 
infl  ammation (Fridman et al., 1987). Up-regulation of heparan-
ase mRNA is correlated with reduced HS in invasive esopha-
geal carcinomas (Mikami et al., 2001), whereas the opposite is 
linked to an increase in overall HS in differentiating myoblasts 
(Barbosa et al., 2005). Our studies did not address whether 
SDC2 and -4 are functional targets of heparanase. Neither 
bound lacritin with or without prior heparitinase treatment. 
Nonetheless, exploration of other ligands may reveal a similar 
capacity for latency in these and other HS proteoglycans.
Heparanase-regulated proliferation has previously been 
attributed to the release of HS-bound FGFs in metastatic breast 
cancer (Kato et al., 1998). Notably, the fi  rst lacritin EST in 
GenBank derives from a subtracted breast cancer library, and 
evidence has been presented for lacritin gene amplifi  cation in 
some metastatic breast cancers (Porter et al., 2003). Others 
have proposed that lacritin is the second most frequent SAGE 
(serial analysis of gene expression) marker for circulating 
breast cancer cells (Bosma et al., 2002). Sdc1 is required for 
Wnt-dependent breast cancer in mice (Alexander et al., 2000) 
and, in human cancers, is up-regulated in some but not others, 
coincident with a role in early proliferative events (Ding et al., 
2005). Thus, lacritin, heparanase, and SDC1 together poten-
tially offer a new paradigm for some human breast cancers.
Although the sequencing data did not expose lacritin’s 
putative signaling receptor, use of pharmacological inhibitors 
and siRNA have identifi  ed proximal signaling elements as Gαi 
or Gαo/PKCα-PLC/Ca
2+/calcineurin/NFATC1/COX2 and Gαi 
or Gαo/PKCα-PLC/PLD1/mTOR (Wang et al., 2006). Both are 
ERK1 and -2 independent and thus contrast with SDC1 cyto-
skeletal signaling. Lacritin signaling may thus involve a 
G   protein–coupled receptor or G protein–dependent ion channel 
that gains ligand affi  nity as a consequence of lacritin immobili-
zation on SDC1. Core protein binding may be stabilized by in-
teraction with HS stubs detected in the lower molecular weight 
heparanase-dependent peak (Fig. 8 D). Interestingly, because 
lacritin- and FGF2-bindable SDC1 pools share some HS chains 
of similar size, not all HS on lacritin-bound SDC1 seem to be 
cleaved. Lack of complete competition of soluble lacritin for 
SDC1 in lacritin affi  nity precipitation assays versus N-24 might 
hypothetically result from folding of lacritin’s more negatively 
charged N terminus onto its positively charged C terminus. 
Cleavage of HS by heparanase to generate lacritin-dependent 
mitogenic activity offers a novel mechanism of epithelial 
 renewal with important implications to the physiology of  human 
exocrine glands.
Collectively, these observations contribute to the growing 
appreciation of mechanisms by which extracellular enzymes 
regulate proteoglycan activity in unexpected ways. Recently de-
scribed Sulf1 and -2 modify the character of HS chains by selec-
tively removing certain 6-O-sulfate groups, thus altering growth 
factor signaling and tumor growth (Dai et al., 2005). Heparanase 
cleavage of HS promotes angiogenesis by solubilizing HS-bound 
Figure 9.  Proposed model of epithelial cell targeting by lacritin. Degly-
canated core protein of SDC1 targets the epithelial selective prosecretory 
mitogen lacritin. (i) Binding requires prior partial or complete removal 
of HS chains by endogenous HPSE1. (ii) Binding is mutually speciﬁ  ed by 
  lacritin’s C-terminal mitogenic domain and SDC1’s N terminus.JCB • VOLUME 174 • NUMBER 7 • 2006  1104
growth factors (Sanderson et al., 2004). This new discovery that 
heparanase removal of HS chains   removes a block to mitogenic 
signaling offers a new regulatory paradigm.
Materials and methods
Cell culture, plasmid constructs, and transfection
The HSG cell line was provided by M. Hoffman (National Institute of 
  Dental and Craniofacial Research, Bethesda MD). HSG cells were cultured 
in DME/F12 with 10% FBS. Cells were assayed between passage 10 and 
20. Some HSG cells were transfected with a SMARTpool of four human 
SDC1 (Ambion) or heparanase-1– or heparanase-2–speciﬁ  c  siRNAs  at 
different doses (Dharmacon). Other cells were transfected with individual 
siRNAs also at different doses. siRNAs sequences are as follows: SDC1 
siRNAs, C  G  A  C  A  A  U  A  A  A  C  G  G  U  A  C  U  U  G  T  T , G  G  A  G  G  A  A  U  U  C  U  A  U  G  C  C  U  G  A  , 
G  G  A  C  U  U  C  A  C  C  U  U  U  G  A  A  A  C  C  T  T  , and G  G  U  A  A  G  U  U  A  A  G  U  A  A  G  U  U  G  A  T  T   
(available from GenBank/EMBL/DDBJ under accession no. NM_002997); 
SDC2 siRNAs, G  G  A  G  U  U  U  U  A  U  G  C  G  U  A  A  A  A  C  T  T  , G  G  A  U  G  U  A  G  A  G  A  G-
U  C  C  A  G  A  G  T  T  , and G  G  A  G  U  G  U  A  U  C  C  U  A  U  U  G  A  U  G  T  T   (available from 
GenBank/EMBL/DDBJ under accession no. NM_002998); heparanase-1 
siRNAs, G  C  A  A  U  G  A  A  C  C  U  A  A  C  A  G  U  U  U  U  U  , G  A  U  C  A  A  A  C  C  U  U  G  C  C  A  C  C-
U  U  U  U  , G  G  A  C  U  G  G  A  C  U  U  G  A  U  C  U  U  U  G  U  U  , and G  A  A  C  A  G  C  A  C  C  U  A  C  U-
C  A  A  G  A  U  U   (available from GenBank/EMBL/DDBJ under accession no. 
NM_006665). Heparanase-2 siRNA sequences from Dharmacon were 
not made publicly available. Also used was Ambion’s negative control 
siRNA #1. Silencing efﬁ  ciency was evaluated by protein blotting and RT-PCR. 
HEK293T cells were purchased from and propagated as suggested by 
American Type Culture Collection. HEK293T cells were transfected with a 
BglII linearized expression vector coding for human SDC1 (hS1-pcDNA3) 
using Lipofectamine 2000 reagent (Invitrogen). Stable populations express-
ing SDC1 were selected in culture medium containing 400 ng/ml G418. 
A human SDC1 deletion construct lacking 51 amino acids from the N ter-
minus (del 1–51) was generated from hS1-pcDNA3 by long-range reverse 
PCR using forward primer 5′-G  G  T  G  G  T  G  G  A  T  C  C  A  C  G  C  A  G  C  T  C  C  T  G  A  C  G-
G  C  T  A  T  T  C  C  C  -3′ and reverse primer 5′-G  G  T  G  G  T  G  G  A  T  C  C  C  A  G  G  C  T  C  A-
G  C  G  C  C  A  G  C  G  C  G  C  A  C  A  G  -3′ containing BamH1 sites. Amplicons were 
cut using BamH1, ligated as plasmid. Human SDC1 del 51–252 (only N-
  terminal 50 amino acids of ectodomain linked to the transmembrane and 
cytoplasmic domains) was similarly generated from hS1-pcDNA3 using 
forward primer 5′-C  T  A  G  C  T  A  G  C  T  T  G  C  A  A  A  G  C  A  C  C  T  G  C  A  C  C  T  G  -3′ and 
  reverse primer 5′-C  T  A  G  C  T  A  G  C  G  A  G  G  T  G  C  T  G  G  G  A  G  G  G  G  T  C  -3′. This in-
troduced NheI sites 5′ of the codon for Ala51 and 3′ of the codon for 
Glu252 (most C-terminal ectodomain amino acid). Amplicons were digested 
with NheI and ligated as plasmid. Human SDC1 del 51–310 (only N-terminal 
50 amino acids of ectodomain) was PCR ampliﬁ   ed from hS1-pcDNA3 
using forward primer 5′-C  T  A  T  A  G  G  G  A  G  A  C  C  C  A  A  G  C  T  T  G  G  T  A  C  C  G  A  G  -3′ 
and reverse primer 5′-C  C  G  G  A  A  T  T  C  A  G  C  A  C  C  T  G  C  A  C  C  T  G  A  G  -3′ contain-
ing HindIII and EcoRI sites. Amplicons were digested with HindIII and 
EcoRI to create cohesive ends and subsequently puriﬁ  ed and ligated into 
the HindIII–EcoRI site of the pcDNA vector. All constructs were conﬁ  rmed 
by DNA sequencing. Plasmids were transfected into HEK293T cells, and 
stable or transient transfectants were generated. Generation of HEK293T 
cells stably transfected with human SDC2 or -4 was previously described 
(Utani et al., 2001). Development of lacritin-intein constructs and puriﬁ  -
cation have been described elsewhere (Wang et al., 2006). A lacritin-
GST construct was prepared by subcloning lacritin cDNA into pGEX4T-2 
(GE Healthcare) using Sap1 and Nde1, in-frame with GST.   Recombinant 
plasmids were transformed into E. coli strain BL21. Bacterial cultures 
were expanded and fusion protein puriﬁ  ed on glutathione–Sepharose 4B 
(GE Healthcare). A human SDC1 ectodomain-GST construct was generated 
from pGEX-2T hS1ED and similarly puriﬁ  ed.
Lacritin afﬁ  nity chromatography
Cell surface biotinylation and afﬁ   nity chromatography followed the 
method of Chen et al. (1997). In brief, six 150-mm culture dishes of 80% 
conﬂ  uent HSG cells were washed twice on ice with ice-cold PBS and incu-
bated for 30 min with EZ-Link Sulfo-NHS-LC Biotin (Pierce Chemical Co.). 
Cells were then washed twice with PBS-glycine, gently loosened with a 
cell scraper, and pelleted at 4°C. The pellet was twice resuspended in 
25 ml PBS-glycine and incubated for 30 min in 1 ml lysis buffer (50 mM 
Tris HCl, pH 7.4, 100 mM NaCl, 5 mM MnCl2, 2 mM PMSF, 200 mM 
n-octyl-β-D-glucopyranoside, and protease inhibitors [Roche Diagnostics]). 
Lysate was centrifuged for 15 min at 4°C, and the supernatant was 
  applied to a 1 ml precolumn, washed through with 1 ml binding buffer 
(50 mM Tris HCl, pH 7.4, 100 mM NaCl, 5 mM MnCl2, 2 mM PMSF, and 
50 mM n-octyl-β-D-glucopyranoside), and collected. Half was applied to a 
lacritin-intein column, in which lacritin was coupled to chitin beads via 
chitin-binding intein, and the other half to a negative control column that 
included an approximately equivalent molar amount of intein-chitin only. 
Columns were rotated end-to-end overnight at 4°C, and each was washed 
with 20 column volumes of afﬁ  nity column buffer and eluted with the same 
buffer containing 1 M NaCl. 20 100-μl fractions were collected per column. 
Fractions were run on 8% SDS-PAGE gels and silver stained or transferred 
to nitrocellulose for blotting with streptavidin peroxidase. For the latter, 
blots were blocked with PBS containing 0.1% Tween 20 and 2.5% milk 
for 1 h at 37°C, washed three times with PBS/0.1% Tween 20, incubated 
in 50 ml of 1:1,000 streptavidin-horseradish peroxidase conjugate 
(GE Healthcare) in PBS/0.1% Tween 20, washed ﬁ  ve times with the same 
buffer, and detected using ECL reagent (Pierce Chemical Co.). Bands of 
interest were excised and sequenced by mass spectroscopy.
Afﬁ  nity precipitation binding
Human SDC1, -2, or -4 stably expressing HEK293T cells were harvested 
on ice into 1 ml of the same lysis buffer used for afﬁ  nity chromatography. 
Lysates were cleared by centrifugation (20,000 g) at 4°C, and protein 
concentration of supernatant was estimated by the BCA assay (Pierce 
Chemical Co.). 5 μg lacritin-intein or lacritin-GST and FGF2-GST fusion 
proteins were bound to chitin beads (New England Biolabs, Inc.) or 
  glutathione–Sepharose beads, respectively. Beads were incubated with 
  lysates ( 200 μg of SDC1 stably expressing HEK293T cells) overnight at 
4°C, and washed three times with afﬁ  nity chromatography binding buffer 
(each wash three times the bead volume). In competition assays, SDC1 ly-
sates were mixed with increasing amounts of soluble lacritin, HS, HS plus 
CS (Seikagaku America), bacterially expressed human SDC1 ectodomain 
(hS1ED), native SDC2, native SDC4, N-24, or C-25. Mixtures were then 
applied to lacritin immobilized beads and further studied. For sequential 
pull-down assays, cell lysates were sequentially afﬁ  nity precipitated with 
FGF2-GST or lacritin-intein. After FGF2-GST depletion of all available FGF-
bindable SDC1, one half was precipitated with lacritin-intein. The other 
half was methanol precipitated overnight and resuspended in heparitinase 
buffer. Similarly, after lacritin-intein depletion of all available lacritin-
  bindable SDC1, one half was precipitated with FGF2-GST and the other 
half precipitated by methanol overnight and resuspended in heparitinase 
  buffer. The reactions were separated by SDS-PAGE and blotted using 
  anti-SDC1 mAb B-B4 (Serotec) or anti-SDC2 polyclonal antibody L-18 or 
anti-SDC4 polyclonal antibody N-19 (Santa Cruz Biotechnology, Inc.) 
  followed by ECL detection.
For SDS-PAGE and immunoblotting, beads were digested with 
heparitinase I (Seikagaku America) and chondroitin ABC lyase (MP Bio-
chemicals) because native syndecans migrate as a heterodisperse smear 
in SDS-PAGE. In brief, beads were resuspended in heparitinase buffer 
(50 mM Hepes, pH 6.5, 50 mM NaOAc, 150 mM NaCl, and 5 mM 
CaCl2) with 0.0001 U heparitinase and 0.005 U chondroitin ABC lyase 
for 2 h at 37°C. A second aliquot of each enzyme was added for an 
addi  tional 2 h. Samples were diluted with 2× sample buffer, separated 
by 10% SDS-PAGE, transferred to Immobilon-P polyvinylidene diﬂ  uoride 
(Millipore) for 4 h at 300 mA, ﬁ  xed for 30 min in PBS containing 0.05% 
glutaraldehyde (Sigma-Aldrich), and blocked overnight at 4°C in TBS 
(10 mM Tris and 150 mM NaCl, pH 7.4) with 3% BSA. mAb B-B4 diluted 
in blocking buffer was incubated with blots for 2 h at RT, washed ﬁ  ve 
times with 10 mM Tris and 150 mM NaCl, pH 7.4, containing 0.1% 
Tween 20, and detected with alkaline-phosphatase–conjugated second-
ary antibody (GE Healthcare) using ECL.
Heparanase detection
For analysis, cellular heparanase was enriched by HiTrap heparin afﬁ  nity 
puriﬁ  cation (GE Healthcare). In brief, HSG or HEK293 lysates were dia-
lyzed overnight against binding buffer (10 mM sodium phosphate, pH 7) 
and applied to the column. After washing with 10 column volumes of bind-
ing buffer, heparanase was eluted using 5 column volumes of elution buffer 
(10 mM sodium phosphate and 2 M NaCl, pH 7). Protein concentration 
was determined by BCA and analyzed by 10% SDS-PAGE. Heparanase-1 
was detected with rabbit polyclonal antibodies directed against human 
heparanase (provided by I. Vlodavsky, Rappaport Faculty of Medicine, 
Haifa, Israel) followed by HRP-conjugated secondary antibody and ECL.
Mitogenesis assay
HSG cells in serum-containing media were seeded in 24-well plates at a 
density of 0.5 × 10
5 cells/well. After 24 h, the medium was changed to 
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lacritin was added for 24 h to a ﬁ  nal concentration of 10 nM in the same 
medium containing 2 μCi/ml [
3H]-thymidine. Cells were incubated alone 
with lacritin or together with an increasing amount of bacterial-expressed 
human SDC1 ectodomain (hS1ED) as a soluble inhibitor. Cells depleted of 
heparanase-1 or SDC1 were treated with lacritin in [
3H]-thymidine 48 h 
  after siRNA transfection. To rescue heparanase-depleted cells,  1 μg hep-
aranase enriched from HSG or HEK293 cells using heparin afﬁ  nity column 
or 0.0001 U bacterial heparitinase (Seikagaku America) was added to-
gether with lacritin and [
3H]-thymidine for 24 h. [
3H]-thymidine incorpora-
tion was stopped by placing on ice. Cultures were washed twice with 
ice-cold PBS, ﬁ  xed with cold and RT TCA (10%) for 10 min each, washed 
twice with RT PBS, collected in 1 N NaOH, neutralized with 1 N HCl, and 
transferred to liquid scintillation vials for measurement.
HS chain analysis
50% conﬂ  uent HSG cell cultures in 150-mm culture dishes were metaboli-
cally labeled with 50 μCi/ml Na2
35SO4 (1494 Ci/mmol; PerkinElmer) in 
DME for 48 h as described by Zako et al. (2003). Both normal and hepa-
ranase-1–depleted cells were labeled. After washing three times with PBS, 
cell lysates were collected and afﬁ  nity precipitated with FGF2-GST or lacri-
tin-intein overnight at 4°C. SDC1 bound to beads was digested with chon-
droitin ABC lyase (MP Biochemicals) for 3 h at 37°C, eluted with 2 M 
NaCl, and subjected to eliminative cleavage and reduction of HS by ad-
justing to 100 mM NaOH/1 M NaBH4 for 24 h at 37°C. Released HS was 
neutralized by drop-wise addition of 1 M HCl and subjected to Sepharose 
CL-6B column (1 × 57 cm) gel ﬁ  ltration chromatography in PBS at a ﬂ  ow 
rate 16 ml/h. Radioactivity was measured by liquid scintillation counting. 
The void volume (V0, fraction 26) and total column volume (Vt, fraction 62) 
were determined using dextran blue and sodium dichromate, respectively, 
as markers.
Online supplemental material
Fig. S1 displays the size heterogeneity of native SDC1 attributable to its HS 
and CS chains. Fig. S2 demonstrates that heparanase and heparitianase 
alone are not mitogenic for HSG cells. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200511134/DC1.
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